Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2018
At a glance
- Drugs PLX 8394 (Primary) ; Cobicistat
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Plexxikon
- 25 Apr 2018 Planned number of patients changed from 107 to 150.
- 25 Apr 2018 Planned End Date changed from 1 Apr 2018 to 1 Jul 2021.
- 25 Apr 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2021.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History